Phaseline

Targets › RHD

RHD (Blood group Rh(D) polypeptide): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Hematology; next expected readout Apr 2029.

May be part of an oligomeric complex which is likely to have a transport or channel function in the erythrocyte membrane. (UniProt, Q02161)

Open in Phaseline: the race on RHD, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Children's Hospital of PhiladelphiaRH genotype matched RBC transfusions
Transfusion of red blood cells matched at RHD and RHCE loci to reduce alloimmunization
RHD, RHCEPhase 1Sickle Cells DiseaseApr 2029

Conditions

Sickle Cells Disease (1)

Modalities

other (1)

Companies

Children's Hospital of Philadelphia (1)

Related targets

RHCE (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.